EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Pharmacodynamic effects of cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII Registry

Giuseppe Gargiulo, Plinio Cirillo, Luca Sperandeo, Domenico Simone Castiello, Lina Manzi, Imma Forzano, Domenico Florimonte, Fiorenzo Simonetti, Mario Enrico Canonico, Marisa Avvedimento, Roberta Paolillo, Alessandra Spinelli und 8 weitere

EuroIntervention · 2025-05 · 21 (10) · 560-570

DOI: 10.4244/eij-d-24-00757 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift EuroIntervention, 2025-05. Verfasst von Giuseppe Gargiulo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Adenosine Monophosphate, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cangrelor is approved for oral P2Y12 inhibitor-naïve patients undergoing percutaneous coronary intervention (PCI). Pharmacodynamic (PD) investigations in various clinical settings, with various assays, have shown contrasting data in terms of the extent of platelet inhibition and rates of high residual platelet reactivity (HRPR). AIMS: We aimed to assess the PD effects of cangrelor in all patients receiving it during PCI. METHODS: PharmacOdynaMic Effects of Cangrelor in PatiEnts wIth Acute or chronIc Coronary Syndrome Undergoing Percutaneous Coronary Intervention (POMPEII Registry; ClinicalTrials.gov: NCT04790032) is an investigator-initiated, prospective study assessing PD effects at 4 timepoints with 3 assays. Clinical outcomes at 30 days were also assessed. RESULTS: From March 2021 to June 2024, 150 patients undergoing PCI and receiving cangrelor were enrolled (64 patients underwent elective PCI; 30 had non-ST-elevation acute coronary syndrome; and 56 had ST-segment elevation myocardial infarction [STEMI], of whom 24 were pretreated with ticagrelor). Most patients switched from cangrelor to either clopidogrel or ticagrelor. Inhibition of platelet aggregation was moderate during cangrelor infusion (light transmittance aggregometry with adenosine diphosphate 20 μM: 57.6±16.5%), with rates of 3.2% for HRPR and 1.3% for bailout tirofiban. Rates of HRPR were relevant at 3 h (37.9%) and 4-6 h (15.3%), and HRPR occurred significantly more frequently in patients switching to clopidogrel compared with ticagrelor. Rates of ischaemic and bleeding events were low. CONCLUSIONS: Cangrelor provided effective platelet inhibition in most patients with ACS or CCS undergoing PCI, including those with STEMI who were pretreated with ticagrelor. Switching from cangrelor to an oral P2Y12 inhibitor, mainly clopidogrel, exposed a large number of patients to a variable period of on-treatment HRPR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeAdenosine MonophosphatePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsAgedFemaleHumansMaleMiddle AgedProspective StudiesPurinergic P2Y Receptor AntagonistsRegistriesTicagrelorTreatment Outcome

Substanzen

Adenosine MonophosphatecangrelorPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsTicagrelor

Autor:innen und Institutionen

  • Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.
  • Cardiovascular Department, Azienda Ospedaliera Regionale "San Carlo", Potenza, Italy.
  • Cardiocentro Institute, Ente Ospedaliero Cantonale, Università della Svizzera Italiana (USI), Lugano, Switzerland.

Zitieren

APA

Gargiulo, G., Cirillo, P., Sperandeo, L., Castiello, D. S., Manzi, L., Forzano, I., Florimonte, D., Simonetti, F., Canonico, M. E., Avvedimento, M., Paolillo, R., Spinelli, A., Buongiorno, F., Serafino, L. D., Spaccarotella, C. A. M., Franzone, A., Piccolo, R., Stabile, E., Valgimigli, M., & Esposito, G. (2025). Pharmacodynamic effects of cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII Registry. EuroIntervention, 21(10), 560-570. https://doi.org/10.4244/eij-d-24-00757

Vancouver

Gargiulo G, Cirillo P, Sperandeo L, Castiello DS, Manzi L, Forzano I, et al. Pharmacodynamic effects of cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII Registry. EuroIntervention. 2025;21(10):560-570. doi:10.4244/eij-d-24-00757

BibTeX
@article{Gargiulo2025,
  author = {Gargiulo, Giuseppe and Cirillo, Plinio and Sperandeo, Luca and Castiello, Domenico Simone and Manzi, Lina and Forzano, Imma and Florimonte, Domenico and Simonetti, Fiorenzo and Canonico, Mario Enrico and Avvedimento, Marisa and Paolillo, Roberta and Spinelli, Alessandra and Buongiorno, Federica and Serafino, Luigi Di and Spaccarotella, Carmen Anna Maria and Franzone, Anna and Piccolo, Raffaele and Stabile, Eugenio and Valgimigli, Marco and Esposito, Giovanni},
  title = {Pharmacodynamic effects of cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII Registry},
  journal = {EuroIntervention},
  year = {2025},
  volume = {21},
  number = {10},
  pages = {560--570},
  doi = {10.4244/eij-d-24-00757}
}
Kostenlos starten →